Skip to Main Content

INFORMATION FOR

Jennifer Sherr, MD, PhD

Professor in Pediatrics (Endocrinology)

Research Summary

My research is related to clinically meaningful investigations to reduce the burden of living with type 1 diabetes through the use of new technologies and therapeutics, improved understanding of the disease process, and strategies to allow youth with type 1 diabetes to attain targeted glycemic control.

Coauthors

Research Interests

Diabetes Mellitus, Type 1

Selected Publications

  • 100-LB: Glycemic Control Using Recommended Settings in Youth and Adults with Type 1 Diabetes (T1D) —Minimed 780G System with the Calibration-Free Guardian 4 Sensor ResultsVIGERSKY R, BODE B, BRAZG R, BUCKINGHAM B, CARLSON A, KAISERMAN K, KIPNES M, LILJENQUIST D, PHILIS-TSIMIKAS A, PIHOKER C, POP-BUSUI R, REED J, SHERR J, SHULMAN D, SLOVER R, THRASHER J, CHEN X, LIU M, CORDERO T, VELLA M, RHINEHART A, SHIN J. 100-LB: Glycemic Control Using Recommended Settings in Youth and Adults with Type 1 Diabetes (T1D) —Minimed 780G System with the Calibration-Free Guardian 4 Sensor Results Diabetes 2022, 71 DOI: 10.2337/db22-100-lb.
  • 908-P: A Self-Assessment: Understanding Perceptions of New-Onset Type 1 Diabetes (T1D) Education in a Pediatric Tertiary Care CenterBETANCUR G, BREI M, WEYMAN K, CARRIA L, STEPHENSON K, VAN NAME M, SHERR J. 908-P: A Self-Assessment: Understanding Perceptions of New-Onset Type 1 Diabetes (T1D) Education in a Pediatric Tertiary Care Center Diabetes 2021, 70 DOI: 10.2337/db21-908-p.
  • 917-P: Supervised Basal Insulin Injections Prevent Ketosis in Youth with Type 1 Diabetes (T1D)NALLY L, SOSNOSKI O, SOSNOSKI O, SHERR J, TICHY E, TICHY E, WEYMAN K, STEFFEN A, MCCOLLUM S, SHABANOVA V, TAMBORLANE W, VAN NAME M. 917-P: Supervised Basal Insulin Injections Prevent Ketosis in Youth with Type 1 Diabetes (T1D) Diabetes 2021, 70 DOI: 10.2337/db21-917-p.
  • 32-LB: Interstitial Glucose Levels during Exercise in Persons with and without Type 1 DiabetesRIDDELL M, LI Z, DSOUZA N, YEUNG C, KESIBI D, PATTON S, BECK R, JACOBS P, CLEMENTS M, GAL R, DOYLE F, MARTIN C, CALHOUN P, SHERR J, CASTLE J, RICKELS M. 32-LB: Interstitial Glucose Levels during Exercise in Persons with and without Type 1 Diabetes Diabetes 2021, 70 DOI: 10.2337/db21-32-lb.
  • 70-OR: Evaluation of the Omnipod 5 Automated Insulin Delivery System in Very Young Children with Type 1 Diabetes (T1D)SHERR J, BODE B, FORLENZA G, LAFFEL L, BROWN S, BUCKINGHAM B, CRIEGO A, DESALVO D, MACLEISH S, HANSEN D, LY T. 70-OR: Evaluation of the Omnipod 5 Automated Insulin Delivery System in Very Young Children with Type 1 Diabetes (T1D) Diabetes 2021, 70 DOI: 10.2337/db21-70-or.
  • 717-P: Real-World, Patient-Reported Data on Training and Use of 670G Hybrid Closed-Loop (HCL) among Children and Adults with Type 1 Diabetes (T1D)BAUZA C, DUBOSE S, VERDEJO A, BECK R, BERGENSTAL R, SHERR J. 717-P: Real-World, Patient-Reported Data on Training and Use of 670G Hybrid Closed-Loop (HCL) among Children and Adults with Type 1 Diabetes (T1D) Diabetes 2021, 70 DOI: 10.2337/db21-717-p.
  • 96-LB: Glycemic Management over 6 Months with the Omnipod 5 Automated Insulin Delivery SystemCARLSON A, CRIEGO A, FORLENZA G, BODE B, LEVY C, HANSEN D, HIRSCH I, BROWN S, BERGENSTAL R, SHERR J, MEHTA S, LAFFEL L, SHAH V, BHARGAVA A, WEINSTOCK R, MACLEISH S, DESALVO D, JONES T, ALEPPO G, BUCKINGHAM B, LY T. 96-LB: Glycemic Management over 6 Months with the Omnipod 5 Automated Insulin Delivery System Diabetes 2021, 70 DOI: 10.2337/db21-96-lb.
  • Safety Evaluation of the Omnipod® 5 Automated Insulin Delivery System Over Three Months of Use in Adults and Adolescents With Type 1 Diabetes (T1D)Brown S, Levy C, Hirsch I, Bode B, Carlson A, Shah V, Pinsker J, Weinstock R, Bhargava A, Mehta S, Laffel L, Jones T, Sherr J, Aleppo G, Forlenza G, Ly T. Safety Evaluation of the Omnipod® 5 Automated Insulin Delivery System Over Three Months of Use in Adults and Adolescents With Type 1 Diabetes (T1D) Journal Of The Endocrine Society 2021, 5: a671-a672. DOI: 10.1210/jendso/bvab048.1370.
  • Safety Evaluation of the Omnipod® 5 Automated Insulin Delivery System Over Three Months of Use in Children With Type 1 Diabetes (T1D)Buckingham B, Forlenza G, Criego A, Hansen D, Bode B, Brown S, MacLeish S, Pinsker J, DeSalvo D, Sherr J, Mehta S, Laffel L, Bhargava A, Ly T. Safety Evaluation of the Omnipod® 5 Automated Insulin Delivery System Over Three Months of Use in Children With Type 1 Diabetes (T1D) Journal Of The Endocrine Society 2021, 5: a454-a454. PMCID: PMC8090047, DOI: 10.1210/jendso/bvab048.927.
  • Adjunctive Therapies for Type 1 DiabetesNally L, Van Name M, Tamborlane W, Sherr J. Adjunctive Therapies for Type 1 Diabetes 2021, 143-150. DOI: 10.1007/978-3-030-64133-7_13.
  • 145-OR: GLP-1 Analogue Effects on Neural Responses to High-Fructose Corn Syrup and Eating Behavior in ObesityJOSEPH K, LEVENTHAL J, HWANG S, KNIGHT M, SEO D, LACADIE C, VAN NAME M, CAPRIO S, SHERR J, TAMBORLANE W, SINHA R, JASTREBOFF A. 145-OR: GLP-1 Analogue Effects on Neural Responses to High-Fructose Corn Syrup and Eating Behavior in Obesity Diabetes 2020, 69 DOI: 10.2337/db20-145-or.
  • 1296-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Children Aged 2-12 Years without Increasing Risk of HypoglycemiaSHERR J, BUCKINGHAM B, FORLENZA G, GALDERISI A, EKHLASPOUR L, WADWA R, ZGORSKI M, KINGMAN R, BERGET C, LEE J, OCONNOR J, DUMAIS B, VIENNEAU T, HUYETT L, LY T. 1296-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Children Aged 2-12 Years without Increasing Risk of Hypoglycemia Diabetes 2020, 69 DOI: 10.2337/db20-1296-p.
  • 1304-P: Glycemic Trends in a Hockey Camp for Youth with Type 1 Diabetes (T1D)RIDDELL M, LI Z, GAL R, MAZZUOCCOLO A, GREENE E, CALHOUN P, BEAULIEU L, CLEMENTS M, SHERR J, PATTON S, BECK R. 1304-P: Glycemic Trends in a Hockey Camp for Youth with Type 1 Diabetes (T1D) Diabetes 2020, 69 DOI: 10.2337/db20-1304-p.
  • 1580-P: Hemoglobin A1c (HbA1c) Trajectories of Youth with Type 1 Diabetes (T1D) over 10 Years Postdiagnosis from Three ContinentsSHERR J, SCHWANDT A, PHELAN H, CLEMENTS M, HOLL R, BENITEZ-AGUIRRE P, MILLER K, WOELFLE J, DOVER T, MAAHS D, FRÖHLICH-REITERER E, CRAIG M. 1580-P: Hemoglobin A1c (HbA1c) Trajectories of Youth with Type 1 Diabetes (T1D) over 10 Years Postdiagnosis from Three Continents Diabetes 2020, 69 DOI: 10.2337/db20-1580-p.
  • 978-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Adults and Adolescents without Increasing Risk of HypoglycemiaFORLENZA G, BUCKINGHAM B, SHERR J, WADWA R, GALDERISI A, EKHLASPOUR L, BERGET C, HSU L, ZGORSKI M, LEE J, OCONNOR J, DUMAIS B, VIENNEAU T, HUYETT L, LY T. 978-P: Omnipod Personalized MPC Algorithm at Target Glucose of 110mg/dl Is Safe in Adults and Adolescents without Increasing Risk of Hypoglycemia Diabetes 2020, 69 DOI: 10.2337/db20-978-p.
  • Chapter 16 The dawn of automated insulin delivery: from promise to productNally L, Sherr J. Chapter 16 The dawn of automated insulin delivery: from promise to product 2020, 327-356. DOI: 10.1016/b978-0-12-816714-4.00016-8.
  • Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: International comparison from the T1D Exchange and DPV InitiativeDJ D, KM M, JM H, DM M, SE H, MA C, E L, JL S, M T, RW H. Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: International comparison from the T1D Exchange and DPV Initiative 2019 DOI: 10.1530/ey.16.10.9.
  • 80-LB: Effect of a Behavioral Economics Intervention on Adherence and Glycemic Outcomes in Youth with T1DNALLY L, WAGNER J, VAN NAME M, SHERR J, ZAJAC K, FINNEGAN J, TAMBORLANE W. 80-LB: Effect of a Behavioral Economics Intervention on Adherence and Glycemic Outcomes in Youth with T1D Diabetes 2019, 68 DOI: 10.2337/db19-80-lb.
  • 1355-P: HbA1c Trajectories from Time of Diagnosis in Youth with T1DSHERR J, FOSTER N, BETHIN K, FOX L, MASTRANDREA L, NATHAN B, REDONDO M, SILVERSTEIN J, SIMMONS J, CLEMENTS M, TAMBORLANE W, THRAILKILL K, WONG J, WOOD J. 1355-P: HbA1c Trajectories from Time of Diagnosis in Youth with T1D Diabetes 2019, 68 DOI: 10.2337/db19-1355-p.
  • 926-P: Frequency of Hypoglycemia by Gender in Healthy Individuals without Diabetes—Not So Different After AllDUBOSE S, LI Z, SHAH V, SHERR J, TAMBORLANE W, BERGENSTAL R, BECK R. 926-P: Frequency of Hypoglycemia by Gender in Healthy Individuals without Diabetes—Not So Different After All Diabetes 2019, 68 DOI: 10.2337/db19-926-p.
  • 1424-P: Changes in Device Uptake and Glycemic Control among Pregnant Women with Type 1 Diabetes: Data from the T1D ExchangeLEVY C, FOSTER N, DUBOSE S, AGARWAL S, LYONS S, PETERS A, UWAIFO G, DIMEGLIO L, SHERR J, POLSKY S. 1424-P: Changes in Device Uptake and Glycemic Control among Pregnant Women with Type 1 Diabetes: Data from the T1D Exchange Diabetes 2019, 68 DOI: 10.2337/db19-1424-p.
  • 215-OR: Safety and Performance of the Omnipod Hybrid Closed-Loop System in Young Children Aged 2-6 Years with Type 1 DiabetesBUCKINGHAM B, FORLENZA G, SHERR J, GALDERISI A, EKHLASPOUR L, LEE J, OCONNOR J, DUMAIS B, HUYETT L, LAYNE J, LY T. 215-OR: Safety and Performance of the Omnipod Hybrid Closed-Loop System in Young Children Aged 2-6 Years with Type 1 Diabetes Diabetes 2019, 68 DOI: 10.2337/db19-215-or.
  • 2418-PUB: Incident Diabetes Complications among Women with T1D Based on ParityPOLSKY S, FOSTER N, DUBOSE S, AGARWAL S, LYONS S, PETERS A, UWAIFO G, DIMEGLIO L, SHERR J, LEVY C. 2418-PUB: Incident Diabetes Complications among Women with T1D Based on Parity Diabetes 2019, 68 DOI: 10.2337/db19-2418-pub.
  • Nasal glucagon: a viable alternative to treat insulin-induced hypoglycaemia in adults with type 1 diabetesSuico J, H?velmann U, Zhang S, Shen T, Bergman B, Sherr J, Zijlstra E, Frier B, Plum-M?rschel L, M?nnig E. Nasal glucagon: a viable alternative to treat insulin-induced hypoglycaemia in adults with type 1 diabetes Diabetologie Und Stoffwechsel 2019, 14: s38-s38. DOI: 10.1055/s-0039-1688217.
  • 157 Nasal Glucagon: Potentially Viable Alternative to Treat Insulin-Induced Hypoglycemia in Adults with Type 1 DiabetesSuico J, Hövelmann U, Zhang S, Shen T, Bergman B, Sherr J, Zijlstra E, Frier B, Plum-Morschel L. 157 Nasal Glucagon: Potentially Viable Alternative to Treat Insulin-Induced Hypoglycemia in Adults with Type 1 Diabetes Canadian Journal Of Diabetes 2018, 42: s53. DOI: 10.1016/j.jcjd.2018.08.162.
  • Suppression of Ketogenesis in Type 1 Diabetes Is Not Delayed by SGLT2 Inhibitor TherapySIEBEL S, PATEL N, GALDERISI A, CARRIA L, TAMBORLANE W, SHERR J. Suppression of Ketogenesis in Type 1 Diabetes Is Not Delayed by SGLT2 Inhibitor Therapy Diabetes 2018, 67 DOI: 10.2337/db18-117-lb.
  • Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Adolescents with Type 1 Diabetes over Five Days Under Free-Living ConditionsFORLENZA G, BUCKINGHAM B, SHERR J, PEYSER T, LEE J, OCONNOR J, DUMAIS B, HUYETT L, LAYNE J, LY T. Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Adolescents with Type 1 Diabetes over Five Days Under Free-Living Conditions Diabetes 2018, 67 DOI: 10.2337/db18-1376-p.
  • Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Children Aged 6-12 Years with Type 1 Diabetes over Five Days Under Free-Living ConditionsSHERR J, FORLENZA G, BUCKINGHAM B, PEYSER T, LEE J, OCONNOR J, DUMAIS B, HUYETT L, LAYNE J, LY T. Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Children Aged 6-12 Years with Type 1 Diabetes over Five Days Under Free-Living Conditions Diabetes 2018, 67 DOI: 10.2337/db18-1377-p.
  • Risk Factors for Cardiovascular Disease (CVD) in Adults with Type 1 Diabetes (T1D)MEHTA S, WU M, FOSTER N, POP-BUSUI R, KATZ M, CRANDALL J, BACHA F, NADEAU K, LIBMAN I, HIERS P, MIZOKAMI-STOUT K, DIMEGLIO L, SHERR J, PRATLEY R, AGARWAL S, SNELL-BERGEON J, CENGIZ E, POLSKY S, SHAH V. Risk Factors for Cardiovascular Disease (CVD) in Adults with Type 1 Diabetes (T1D) Diabetes 2018, 67 DOI: 10.2337/db18-15-lb.
  • Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Adults with Type 1 Diabetes over Five Days Under Free-Living ConditionsBUCKINGHAM B, SHERR J, FORLENZA G, PEYSER T, LEE J, OCONNOR J, DUMAIS B, HUYETT L, LAYNE J, LY T. Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Adults with Type 1 Diabetes over Five Days Under Free-Living Conditions Diabetes 2018, 67 DOI: 10.2337/db18-207-or.
  • Increased HbA1c Variability May Shorten Time to Microalbuminuria Development in Type 1 Diabetes (T1D)CLEMENTS M, WU M, FOSTER N, LAFFEL L, SHAH V, VENDRAME F, KINGMAN R, ALONSO G, CARLSON A, DESALVO D, BUCKINGHAM B, SHERR J, BENJAMIN R, EYTH E, DUBOSE S. Increased HbA1c Variability May Shorten Time to Microalbuminuria Development in Type 1 Diabetes (T1D) Diabetes 2018, 67 DOI: 10.2337/db18-26-lb.
  • Future Drug Treatments for Type 1 DiabetesSherr J, Cengiz E, Van Name M, Weinzimer S, Tamborlane W. Future Drug Treatments for Type 1 Diabetes 2016, 985-999. DOI: 10.1002/9781118924853.ch66.

Clinical Trials

ConditionsStudy Title
Diabetes Mellitus - Type 1Metabolic Changes Induced by a Very Low Carbohydrate Diet in Youth With Type 1 Diabetes
Diabetes Mellitus - Type 1TrialNet TOPPLE Study for People with Type 1 Diabetes
Diabetes Mellitus - Type 1Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer) A Proof-of-Concept Study
Children's Health; Diabetes Mellitus - Type 1Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System
Diabetes Mellitus - Type 1Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus (TN-22)
Children's Health; Diabetes Mellitus - Type 1; Diabetes Mellitus - Type 2CGM Intervention in Teens and Young Adults With Type 1 Diabetes (T1D) (CITY)
Diabetes Mellitus - Type 1; Diseases of the Endocrine System; Diseases of the Nervous SystemImpact of Hypoglycemia on Brain Ketone and Neurotransmitter Metabolism in Type 1 DM
Children's Health; Diabetes Mellitus - Type 1; Diseases of the Endocrine SystemPathway to Prevention Study